| Literature DB >> 32082557 |
Nicholas Hargrove1, Quinn Tays2, Leroy Storsley1,3, Paul Komenda1,2,3,4, Claudio Rigatto1,2,3,4, Thomas Ferguson1,2, Navdeep Tangri1,2,3,4, Clara Bohm1,2,3,5.
Abstract
BACKGROUND: Exercise rehabilitation may help maintain physical function in chronic kidney disease (CKD), but long-term clinical effectiveness is unknown. We evaluated the effect of an exercise rehabilitation program on physical function over 1 year in individuals with CKD.Entities:
Keywords: chronic kidney disease; exercise; exercise rehabilitation; physical activity; physical function; quality of life
Year: 2019 PMID: 32082557 PMCID: PMC7025337 DOI: 10.1093/ckj/sfz037
Source DB: PubMed Journal: Clin Kidney J ISSN: 2048-8505
FIGURE 1Participant flow diagram. Exercise Counseling Clinic (ECC).
Comparison of baseline demographics within study group by 1-year follow-up status
| Clinical demographics | Exercise attenders | Exercise nonattenders | CanFIT controls | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Follow-up | No follow-up | P-value | Follow-up | No follow-up | P-value | Follow-up | No follow-up | P-value | |
|
|
|
|
|
|
|
|
| ||
| Age (years) | 63 (12) | 67 (12) | 0.16 | 56 (13) | 57 (15) | 0.7 | 63 (16) | 64 (15) | 0.6 |
| BMI (kg/m2) | 31.2 (6.5) | 30.4 (6.7) | 0.5 | 32.5 (9.2) | 30.7 (7.0) | 0.3 | 29.6 (6.1) | 29.4 (5.8) | 0.8 |
| Race, non-white | 23% (10) | 19% (11) | 0.6 | 26% (9) | 27% (19) | 0.9 | 27% (54) | – | – |
| Gender, male | 51% (27) | 58 (37) | 0.5 | 65% (26) | 51% (47) | 0.1 | 60% (125) | 56% (62) | 0.4 |
| Systolic BP (mmHg) | 138 (18.2) | 143 (23.1) | 0.2 | 138 (23.1) | 140 (22.3) | 0.6 | 138 (21.0) | 141 (24.0) | 0.3 |
| Diastolic BP (mmHg) | 75 (12.2) | 77 (12.4) | 0.4 | 75 (11.0) | 78 (12.7) | 0.2 | 76 (13.3) | 74 (12.5) | 0.4 |
| Arthritis | 38% (20) | 39% (25) | 0.9 | 33% (13) | 32% (30) | 0.9 | 40% (82) | 45% (45) | 0.4 |
| Diabetes | 57% (30) | 45% (29) | 0.2 | 60% (24) | 58% (54) | 0.8 | 58% (120) | 56% (56) | 0.7 |
| High cholesterol | 68% (36) | 57% (36) | 0.2 | 63% (25) | 51% (47) | 0.2 | 61% (126) | 55% (55) | 0.3 |
| IHD | 21% (11) | 23% (15) | 0.7 | 23% (9) | 35% (33) | 0.1 | 18% (38) | 16% (16) | 0.6 |
| PVD | 13% (7) | 9% (6) | 0.5 | 18% (7) | 13% (12) | 0.5 | 17% (36) | 15% (15) | 0.6 |
| Dialysis | 25% (13) | 30% (19) | 0.5 | 58% (23) | 53% (49) | 0.6 | 28% (58) | 15% (17) | 0.01 |
| Smoker (ever) | 34% (18) | 41% (26) | 0.5 | 43% (17) | 38% (35) | 0.6 | – | – | – |
| Walk support | 27% (14) | 38% (23) | 0.2 | 32% (12) | 28% (25) | 0.7 | 28% (21) | 38% (15) | 0.3 |
| Albumin (g/L) | 35 (4.6) | 35 (4.8) | 0.6 | 33 (5.8) | 33 (5.5) | 0.9 | 36 (5.1) | 35 (5.6) | 0.3 |
| Calcium corrected (mmol/L) | 2.4 (0.2) | 2.1 (0.2) | 0.9 | 2.4 (0.2) | 2.4 (0.2) | 0.3 | 2.4 (0.2) | 2.3 (0.2) | 0.7 |
| Creatinine (umol/L) | 215 (146–426) | 265 (161–469) | 0.2 | 481 (189–785) | 445 (181–648) | 0.5 | 306 (210–514) | 319 (222–503) | 0.4 |
| eGFR—MDRD | 30 (18–40) | 24 (18–34) | 0.2 | 24 (16–51) | 31 (18–48) | 0.8 | 19 (14–25) | 17 (11–22) | 0.01 |
| Hemoglobin (g/L) | 119 (17.6) | 116 (15.1) | 0.3 | 114 (17.9) | 113 (18.0) | 0.7 | 114 (15.4) | 111 (16.1) | 0.09 |
| Phosphate (mmol/L) | 1.4 (0.4) | 1.4 (0.5) | 0.9 | 1.6 (0.5) | 1.5 (0.5) | 0.5 | 1.4 (0.3) | 1.5 (0.4) | 0.004 |
| PTH (ng/L) | 155 (89–236) | 168 (76–335) | 0.3 | 176 (118–431) | 232 (111–427) | 0.7 | 171 (91–278) | 182 (103–335) | 0.1 |
Continuous variables are expressed as mean (SD) or median (IQR). Categorical variables are expressed as % (n). Data not collected in a group is indicated with ‘–’. Data for CHF, hypertension, lung disease and stroke proportions were analyzed but suppressed due to cell values <6, per the Manitoba Centre for Health Policy [38].
eGFR calculated only for those individuals not on dialysis in each group.
BP, blood pressure; CHF, congestive heart failure; eGFR, estimated glomerular filtration rate; IHD, ischemic heart disease; PTH, parathyroid hormone; PVD, peripheral vascular disease.
Comparison of baseline outcome measures within groups by 1-year follow-up status
| Outcome measures | Exercise attenders | P-value | Exercise nonattenders | P-value | CanFIT controls | P-value | |||
|---|---|---|---|---|---|---|---|---|---|
| Follow-up | No follow-up | Follow-up | No follow-up | Follow-up | No follow-up | ||||
|
|
|
|
|
|
| ||||
| SPPB score Total | 10.5 (9–12) | 11 (9–12) | 0.6 | 10 (8–12) | 10 (9–12) | 0.4 | 9 (7–11) | 8 (5–11) | 0.06 |
| [52] | [64] | [39] | [93] | [207] | [111] | ||||
| SPPB score (baseline <12) | 10 (7–11) | 9 (8–11) | 0.9 | 9 (8–10) | 9 (8–11) | 0.3 | 8 (5–10) | 7 (4–10) | 0.04 |
| [35] | [39] | [29] | [64] | [162] | [83] | ||||
| EQ-5D-VAS | 62.8 (18.3) | 66.0 (16.7) | 0.4 | 59.6 (18.4) | 53.9 (18.8) | 0.1 | 62.1 (19.6) | 59.5 (20.3) | 0.3 |
| [52] | [54] | [39] | [85] | [189] | [85] | ||||
| HAP MAS | 66.9 (13.7) | 68.9 (13.3) | 0.5 | 65.3 (16.5) | 65.8 (14.8) | 0.9 | – | – | – |
| [51] | [62] | [38] | [92] | ||||||
| HAP AAS | 57.4 (17.0) | 56.3 (17.8) | 0.8 | 50.4 (19.9) | 50.8 (21.3) | 0.9 | – | – | – |
| [49] | [61] | [37] | [84] | ||||||
Continuous variables are expressed as mean (SD) or median (IQR). Number of participants included in analysis indicated by [n]. Data not collected in a group is indicated with ‘–’.
Baseline demographics by study group
| Clinical demographics | Exercise attenders | Exercise nonattenders | CanFIT controls | P-value |
|---|---|---|---|---|
|
|
|
| ||
| Age (years) | 63 (12) | 56 (13) | 63 (16) | 0.008 |
| BMI (kg/m2) | 31.2 (6.5) | 32.5 (9.2) | 29.6 (6.1) | 0.03 |
| Race, non-white | 23% (10) | 26% (9) | 27% (54) | 0.9 |
| Gender, male | 51% (27) | 65% (26) | 60% (125) | 0.3 |
| Systolic BP (mmHg) | 138 (18.2) | 138 (23.1) | 138 (21.0) | 0.9 |
| Diastolic BP (mmHg) | 75 (12.2) | 75 (11.0) | 76 (13.3) | 0.9 |
| Arthritis | 38% (20) | 33% (13) | 40% (82) | 0.7 |
| Diabetes | 57% (30) | 60% (24) | 58% (120) | 0.9 |
| High cholesterol | 68% (36) | 63% (25) | 61% (126) | 0.7 |
| IHD | 21% (11) | 23% (9) | 18% (38) | 0.8 |
| PVD | 13% (7) | 18% (7) | 17% (36) | 0.8 |
| Dialysis | 25% (13) | 58% (23) | 28% (58) | <0.001 |
| Smoker (ever) | 34% (18) | 43% (17) | 0.4 | |
| Walk support | 27% (14) | 32% (12) | 28% (21) | 0.9 |
| Albumin (g/L) | 35 (4.6) | 33 (5.8) | 36 (5.1) | 0.04 |
| Calcium corrected (mmol/L) | 2.4 (0.2) | 2.4 (0.2) | 2.4 (0.2) | 0.007 |
| Creatinine (umol/L) | 215 (146–426) | 481 (189–785) | 306 (210–514) | 0.002 |
| eGFR—MDRD (mL/min/1.73 m2) | 30 (18–40) | 24 (16–51) | 19 (14–25) | <0.0001 |
| Hemoglobin (g/L) | 119 (17.6) | 114 (17.9) | 114 (15.4) | 0.2 |
| Phosphate (mmol/L) | 1.4 (0.4) | 1.6 (0.5) | 1.4 (0.3) | 0.03 |
| PTH (ng/L) | 155 (89–236) | 176 (118–431) | 171 (91–278) | 0.4 |
Continuous variables are expressed as mean (SD) or median (IQR). Categorical variables are expressed as % (n). Data not collected in group is indicated with a blank cell. Data for CHF, hypertension, lung disease, and stroke proportions were analyzed but suppressed due to cell values <6, per the Manitoba Centre for Health Policy [36].
Pairwise comparisons (Tukey’s):
Attenders versus nonattenders P < 0.05.
Attenders versus CanFIT controls P < 0.05.
Nonattenders versus CanFIT controls P < 0.05.
Attenders versus CanFIT controls P < 0.0001 (eGFR calculated only for those individuals not on dialysis in each group; pairwise comparison).
Outcome measures over time by study group
| Outcome measures | Baseline | One year | Mean change over 1 year | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exercise attenders | Exercise nonattenders | CanFIT controls | P-value | Exercise attenders | Exercise nonattenders | CanFIT controls | P-value | Exercise attenders | Exercise nonattenders | CanFIT controls | P-value | |
|
|
|
|
|
|
|
|
|
| ||||
| SPPB score Total | 10.5 | 10 (8–12) | 9 | 0.02 | 11 | 9 (7–12) | 9 (6–11) | 0.02 | −0.06 (2.30) | −0.38 (1.75) | −0.33 (2.33) | 0.7 |
| [52] | [39] | [207] | [49] | [37] | [204] | [48] | [37] | [204] | ||||
| SPPB score (baseline | 10 (7–11) | 9 (8–10) | 8 (5–10) | 0.05 | 10 | 9 (7–11) | 8 (5–10.5) | 0.01 | 0.31 (2.61) | −0.26 (1.83) | −0.23 (2.52) | 0.5 |
| <12) | [35] | [29] | [162] | [33] | [27] | [160] | [32] | [27] | [160] | |||
| EQ-5D-VAS | 62.8 (18.3) | 59.6 (18.4) | 62.1 (19.6) | 0.7 | 62.2 (20.0) | 61.3 (20.3) | 66.3 (17.9) | 0.2 | −0.5 (21.3) | 0.8 (22.0) | 4.4 (21.5) | 0.3 |
| [52] | [39] | [189] | [52] | [35] | [202] | [51] | [34] | [184] | ||||
| HAP MAS | 66.9 (13.7) | 65.3 (16.5) | X | 0.6 | 69.0 (11.7) | 65.1 (17.2) | X | 0.2 | 1.5 (8.4) | 0.2 (10.7) | X | 0.5 |
| [51] | [38] | [51] | [34] | [49] | [33] | |||||||
| HAP AAS | 57.4 (17.0) | 50.4 (19.9) | X | 0.08 | 55.2 (17.3) | 52.3 (19.9) | X | 0.5 | −3.0 (9.5) | 0.5 (9.2) | X | 0.1 |
| [49] | [37] | [51] | [33] | [47] | [31] | |||||||
Continuous variables are expressed as mean (SD) if normally distributed, or expressed median (IQR) if not normally distributed. X = not measured in CanFIT control group.
Number of participants included in analysis indicated by [n].
Pairwise comparisons:
Exercise attenders versus CanFIT controls P < 0.001.
Exercise nonattenders versus CanFIT controls P < 0.001.
Exercise attenders versus CanFIT controls P < 0.004.
Predictors of improvement in SPPB over time in those with Baseline SPPB <12 (n = 218)
| Variable | OR (95% CI) |
|
|---|---|---|
| Exercise rehabilitation attendance | 2.18 (0.95–5.02) | 0.07 |
| Age | 0.99 (0.96–1.01) | 0.2 |
| Sex | 0.91 (0.50–1.64) | 0.2 |
| Albumin | 0.97 (0.91–1.03) | 0.3 |
| Hemoglobin | 1.00 (0.98–1.02) | 0.9 |
| Diabetes | 0.79 (0.43–1.46) | 0.5 |
| SPPB total score at baseline | 0.96 (0.86–1.06) | 0.4 |
| Dialysis versus CKD | 0.72 (0.36–1.46) | 0.3 |
| Transplant versus CKD | 1.42 (0.28–7.23) | 0.5 |
Logistic regression model included: age, sex, serum albumin, hemoglobin, presence of diabetes, baseline SPPB score and category of CKD (CKD versus dialysis; CKD versus transplant).
Proportion of participants endorsing any impairment in EQ-5D-3L domains over time by study group
| Baseline | One-year follow-up | |||||||
|---|---|---|---|---|---|---|---|---|
| Exercise attenders | Exercise nonattenders | CanFIT controls | P-value | Exercise attenders | Exercise nonattenders | CanFIT controls | P-value | |
|
|
|
|
|
|
| |||
| Mobility | 40.4 (21) | 62.5 (25) | 47.4 (91) | 0.1 | 46.2 (24) | 61.1 (22) | 51.7 (106) | 0.4 |
| Self-care | 23.1 (12) | 20.0 (8) | 9.9 (19) | 0.02 | 17.3 (9) | 21.6 (8) | 8.3 (17) | 0.02 |
| Usual activities | 44.2 (23) | 52.5 (21) | 22.4 (43) | <0.001 | 41.2 (21) | 50.0 (18) | 25.9 (53) | 0.004 |
| Pain/discomfort | 63.5 (33) | 74.4 (29) | 55.2 (106) | 0.07 | 71.2 (37) | 77.8 (28) | 50.2 (103) | <0.001 |
| Anxiety/depression | 37.3 (19) | 50.0 (20) | 29.7 (57) | 0.04 | 43.1 (22) | 38.9 (14) | 28.3 (58) | 0.08 |
Proportions are represented as % (n) endorsing any disability in that dimension, i.e. domain score >1. Proportions compared between groups using chi-square testing.
FIGURE 2Proportion of participants reporting regular exercise at baseline and 1 year. Proportions are percentage reporting they are currently exercising ≥30 min at least three times weekly at specified time period. Proportions exercising compared between attenders and nonattenders at specified time period using chi-square test.